ライフサイエンスコーパス: than did

1 e serotonin reuptake inhibitors escitalopram and sertraline than did A allele carriers.

2 continuous combo therapy afforded no greater T1D protection than did BAFFR-Fc alone.

3 ha overexpression more strongly promoted OC differentiation than did c-Fos overexpression.

4 induction treatment and caused fewer severe adverse events than did carboplatin, etoposide, and melphalan.

5 African Americans lost more spine BMD than did Caucasians (-0.04 +/- 0.04 compared with -0.02 +/- 0

6 induced expression in human and mouse cerebellar astrocytes than did cerebral cortical astrocytes, suggesting that IFNAR

7 tients had deterioration in the QLQ-LC13 composite endpoint than did chemotherapy-treated patients (46 [31%] of 151 patie

8 en taking significantly more, but slower and shorter, steps than did CIPN- (all P < .05).

9 icantly worse self-report and objectively measured function than did CIPN-, with the exception of maximal leg strength an

10 ), and it provided greater net clinical benefit to patients than did considering them all to have the same level of risk

11 ibited impairments in contextual memory and spent less time than did controls interacting with an unfamiliar mouse in a s

12 cGAMP and PD-L1 antibody exerted stronger antitumor effects than did either treatment alone.

13 BDG patients had significantly higher cerebral blood flow than did Fontan patients.

14 significantly higher prevalence of tobacco and alcohol use than did high socioeconomic groups.

15 redicted survival and response to chemotherapy in BC better than did histopathological assessment of TILs or gene express

16 the Effort condition made more attempts to achieve the goal than did infants in the other conditions.

17 0.99] and walking (AF: 0.93; 95% CI: 0.88, 0.98) 7% faster than did infants who were exclusively breastfed, but these fi

18 ptionally active histone modifications at M2 gene promoters than did macrophages from male mice.

19 tial weight loss.Regainers had higher body weight at year 4 than did maintainers (mean difference range: 6.6-11.9 kg in L

20 cell implants demonstrated stronger ferumoxytol enhancement than did matched stem cell implants.

21 al, 11% to 18%] higher hospitalization rates, respectively, than did men of respective ages).

22 s interacted with sisters and matriarchs less while feeding than did non-orphans, but otherwise their affiliates were sim

23 and lower incidence rates of hypertension and dyslipidemia than did nonsurgery group 1 (P<0.05 for all comparisons).

24 s than 1 showed dramatically lower recurrence-free survival than did patients with a ratio of greater than 1.

25 with XLP had significantly higher ePPIX levels, on average, than did patients with EPP (3574 vs 1669 microg/dL; P < .001)

26 ents with TAMs had lower CD4 counts at treatment initiation than did patients without TAMs (60.5 cells per muL [IQR 21.0-

27 tase, a marker of mast-cell activation, to a greater extent than did placebo (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng

28 ment reduced airway hyperresponsiveness to a greater extent than did placebo.

29 0.0034) and less time hyperglycaemic (27% vs 32%; p=0.0279) than did pregnant control participants, with comparable sever

30 e showed greater 3' UTR size differences among APA isoforms than did S. cerevisiae PASs in different locations of gene ar

31 lds had higher indoor air concentrations of both pesticides than did samples from non-farmworker households.

32 , SbCCR2, displayed greater activity toward p-coumaroyl-CoA than did SbCCR1, which could imply a role in the synthesis of

33 t diffusion coefficient (beta = -0.3, P = .02, R(2) = 0.33) than did steatosis (beta = -0.5, P < .001, R(2) = 0.33).

34 agmSab replication in sabaeus PBMC and had a greater impact than did the CCR5 blocker maraviroc, confirming the use of CX

35 I: -0.37, -0.03) and DBP (SMD: -0.27; 95% CI: -0.52, -0.03) than did the control group.

36 SIOP detected ototoxicity earlier than did the other scales.

37 rdiomyocytes (p = 0.04), and noncardiomyocytes (p = 0.0002) than did the placebo group in some regions of the heart.

38 2 mutants had catalytic profiles more similar to each other than did the wildtype proteins.

39 living with HIV, had much shorter overall life expectancies than did their HIV-negative counterparts in the general popul

40 (quartile 1) had significantly lower ALM, ALM/ht(2), and QS than did those in the higher quartiles of intake (quartiles 2

41 had higher rates of skin redness, tinnitus, and nervousness than did those in the other two groups, and new-onset mania d

42 g escitalopram had more frequent sleepiness and obstipation than did those in the other two groups.

43 iving with HIV on ART had lower prevalence of high-risk HPV than did those not on ART (adjusted odds ratio [aOR] 0.83, 95

44 d pups at high ambient temperatures produced fewer recruits than did those rearing pups in cooler weather; at the non-sea

45 benefit thresholds had a lower median incremental drug cost than did those that did not meet benefit thresholds (US$2981

46 better scores with respect to behavior and quality of life than did those who continued medical therapy alone at 12 mont

47 e clinical response criteria for the two primary end points than did those who received placebo.

48 re comorbid conditions, and experienced more severe strokes than did those who were not on anticoagulation (median Nation

49 cted more against methotrexate-induced gastrointestinal AEs than did weekly administration.

50 WAZ) predicted inpatient and postdischarge mortality better than did WLZ (P < 0.0001).